HomeMANKIND • NSE
add
Mankind Pharma Ltd
Previous close
₹2,456.70
Day range
₹2,425.55 - ₹2,508.05
Year range
₹1,901.05 - ₹3,054.80
Market cap
1.02T INR
Avg Volume
716.95K
P/E ratio
46.96
Dividend yield
-
Primary exchange
NSE
In the news
Financials
Income Statement
Revenue
Net income
| (INR) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 32.30B | 23.90% |
Operating expense | 16.57B | 29.21% |
Net income | 3.80B | -16.20% |
Net profit margin | 11.77 | -32.40% |
Earnings per share | 9.44 | -16.53% |
EBITDA | 7.34B | 27.38% |
Effective tax rate | 22.68% | — |
Balance Sheet
Total assets
Total liabilities
| (INR) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 47.27B | 103.22% |
Total assets | — | — |
Total liabilities | — | — |
Total equity | 107.89B | — |
Shares outstanding | 402.36M | — |
Price to book | 9.32 | — |
Return on assets | — | — |
Return on capital | 14.14% | — |
Cash Flow
Net change in cash
| (INR) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 3.80B | -16.20% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
Founded
1991
Website
Employees
19,540
